DOJOLVI is the first and only FDA-approved prescription treatment for long-chain fatty oxidation disorders (LC-FAOD)

Discover DOJOLVI to help your patients reach their goals

The first and only prescription drug available in Canada indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Assistance in gaining access to DOJOLVI

UltraCare services are designed to help facilitate patient access to DOJOLVI treatment.

Enrolling in UltraCare may help your patients to:

  • Understand their insurance coverage
  • Access resources in the Patient Support Program

Download a DOJOLVI Patient Enrolment Form to start the enrolment process

Fill out the form with your patient and fax it to 1-833-592-2273 (CARE). Please note that a completed form is required for your enrolment.


For additional support, please call 1-833-388-5872 (U-LTRA).

LESS

Indication and clinical use

DOJOLVI™ (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at www.ultragenyx.com/canada/medicines/dojolvi-product-monograph-CANADA/ for important information on warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

Indication and clinical use

DOJOLVI™ (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at www.ultragenyx.com/canada/medicines/dojolvi-product-monograph-CANADA/ for important information on warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

For additional information and questions about medical information or medical affairs, please contact Ultragenyx Medical Affairs at 1-833-388-5872 (U-LTRA).